Estefania Contreras Aviles,Mildred Philippe Ponce,Ariadna Guinea Lagunes,Santos Gerardo Almeida del Prado,Valeria Natalie Sebastian Ocampo,Raquel Yazmin López Perez,Billy Jiménez Bobadilla,Jorge Luis De León Rendón

Abstract:Ulcerative colitis (UC) is a chronic inflammatory disease that primarily affects the colonic mucosa, significantly impairing patient's quality of life. Vedolizumab (VDZ), a humanized monoclonal antibody, targets the α4β7 integrin on leukocytes, inhibiting their interaction with mucosal addressin cell adhesion molecule 1 (MAdCAM-1) and thereby restricting lymphocyte migration to intestinal tissue. VDZ is indicated for moderate to severe UC in patients who have not responded to conventional therapies or tumor necrosis factor-α antagonists and has demonstrated efficacy as a first-line treatment for UC. However, real-world data on VDZ's effectiveness in Latin America and Mexico is limited. This study aims to assess the impact of VDZ treatment over a 12-week period in UC patients by evaluating both clinical and biochemical parameters.

S85 Clinical Impact of Vedolizumab Treatment in Patients With Ulcerative Colitis: Evidence from a Real-World Study in Mexico